Development of EBV Related Diffuse Large B-cell Lymphoma in Deficiency of Adenosine Deaminase 2 with Uncontrolled EBV Infection.

Humans Lymphoma, Large B-Cell, Diffuse / etiology Epstein-Barr Virus Infections / complications Adenosine Deaminase / deficiency Herpesvirus 4, Human Intercellular Signaling Peptides and Proteins / deficiency Male Female Hereditary Autoinflammatory Diseases
Deficiency of Adenosine Deaminase 2 Diffuse Large B-cell Lymphoma EBV

Journal

Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137

Informations de publication

Date de publication:
17 May 2024
Historique:
received: 27 11 2023
accepted: 17 04 2024
medline: 17 5 2024
pubmed: 17 5 2024
entrez: 17 5 2024
Statut: epublish

Résumé

Deficiency of Adenosine Deaminase 2 (DADA2) patients presenting with primary immunodeficiency are at risk of uncontrolled EBV infection and secondary malignancies including EBV-related lymphoproliferative disorders (LPD). This paper describes the first case of EBV related diffuse large B-cell lymphoma in a patient with DADA2 and uncontrolled EBV infection. Consideration should be given to monitoring for EBV viraemia and to preventative EBV specific therapy in DADA2 and patients with at risk primary immunodeficiencies. A type I interferon (IFN) gene signature is associated with DADA2 though its association with immune dysregulation is unclear.

Identifiants

DOI: 10.1007/s10875-024-01712-x PMID: 38758417
pubmed: 38758417
doi: 10.1007/s10875-024-01712-x
pii: 10.1007/s10875-024-01712-x
doi:

Substances chimiques

ADA2 protein, human 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

118

Informations de copyright

© 2024. The Author(s).

Références

Brooks JP, Rice AJ, Ji W, Lanahan SM, Konstantino M, Dara J, et al. Uncontrolled Epstein-Barr Virus as an atypical presentation of Deficiency in ADA2 (DADA2). J Clin Immunol. 2021;41(3):680–3.
doi: 10.1007/s10875-020-00940-1 pubmed: 33394316
Lee PY, Vasculopathy. Immunodeficiency, and bone marrow failure: the Intriguing Syndrome caused by Deficiency of Adenosine Deaminase 2. Front Pediatr. 2018;6:282.
doi: 10.3389/fped.2018.00282 pubmed: 30406060 pmcid: 6200955
Aksentijevich I, Sampaio Moura N, Barron K. Adenosine Deaminase 2 Deficiency. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, editors. GeneReviews((R)). Seattle (WA)1993.
Crombie JL, LaCasce AS. Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative disorders. Front Oncol. 2019;9:109.
doi: 10.3389/fonc.2019.00109 pubmed: 30899698 pmcid: 6416204
Melani C, Jaffe ES, Wilson WH. Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder. Blood. 2020;135(16):1344–52.
doi: 10.1182/blood.2019000933 pubmed: 32107539 pmcid: 7162687
Houen G, Trier NH. Epstein-Barr Virus and systemic Autoimmune diseases. Front Immunol. 2020;11:587380.
doi: 10.3389/fimmu.2020.587380 pubmed: 33488588
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–48.
doi: 10.1038/s41375-022-01620-2 pubmed: 35732829 pmcid: 9214472
Yap JY, Moens L, Lin MW, Kane A, Kelleher A, Toong C, et al. Intrinsic defects in B cell development and differentiation, T cell exhaustion and altered unconventional T cell Generation Characterize Human Adenosine Deaminase Type 2 Deficiency. J Clin Immunol. 2021;41(8):1915–35.
doi: 10.1007/s10875-021-01141-0 pubmed: 34657246 pmcid: 8604888
Van Montfrans JM, Hartman EA, Braun KP, Hennekam EA, Hak EA, Nederkoorn PJ, et al. Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. Rheumatology (Oxford). 2016;55(5):902–10.
doi: 10.1093/rheumatology/kev439 pubmed: 26867732
Rice GI, Melki I, Frémond ML, Briggs TA, Rodero MP, Kitabayashi N, et al. Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease. J Clin Immunol. 2017;37(2):123–32.
doi: 10.1007/s10875-016-0359-1 pubmed: 27943079
Jiang Y, Firan M, Nandiwada SL, Reyes A, Marsh RA, Vogel TP, et al. The natural history of X-Linked lymphoproliferative disease (XLP1): lessons from a long-term Survivor. Case Rep Immunol. 2020;2020:8841571.
Dimitriades VR, Devlin V, Pittaluga S, Su HC, Holland SM, Wilson W, et al. DOCK 8 Deficiency, EBV + Lymphomatoid granulomatosis, and Intrafamilial Variation in Presentation. Front Pediatr. 2017;5:38.
doi: 10.3389/fped.2017.00038 pubmed: 28293550 pmcid: 5328973
Insalaco A, Moneta GM, Pardeo M, Caiello I, Messia V, Bracaglia C, et al. Variable clinical phenotypes and Relation of Interferon Signature with Disease Activity in ADA2 Deficiency. J Rheumatol. 2019;46(5):523–6.
doi: 10.3899/jrheum.180045 pubmed: 30647181
Skrabl-Baumgartner A, Plecko B, Schmidt WM, König N, Hershfield M, Gruber-Sedlmayr U, et al. Autoimmune phenotype with type I interferon signature in two brothers with ADA2 deficiency carrying a novel CECR1 mutation. Pediatr Rheumatol Online J. 2017;15(1):67.
doi: 10.1186/s12969-017-0193-x pubmed: 28830446 pmcid: 5568374
Nihira H, Izawa K, Ito M, Umebayashi H, Okano T, Kajikawa S, et al. Detailed analysis of Japanese patients with adenosine deaminase 2 deficiency reveals characteristic elevation of type II interferon signature and STAT1 hyperactivation. J Allergy Clin Immunol. 2021;148(2):550–62.
doi: 10.1016/j.jaci.2021.01.018 pubmed: 33529688
Balfour HH Jr., Hokanson KM, Schacherer RM, Fietzer CM, Schmeling DO, Holman CJ, et al. A virologic pilot study of valacyclovir in infectious Mononucleosis. J Clin Virol. 2007;39(1):16–21.
doi: 10.1016/j.jcv.2007.02.002 pubmed: 17369082
Stefanou C, Tzortzi C, Georgiou F, Timiliotou C. Combining an antiviral with rituximab in EBV-related haemophagocytic lymphohistiocytosis led to rapid viral clearance; and a comprehensive review. BMJ Case Rep. 2016;2016.
Linden DA, Guo-Parke H, McKelvey MC, Einarsson GG, Lee AJ, Fairley DJ, et al. Valaciclovir for Epstein-Barr Virus suppression in moderate-to-severe COPD: a Randomized double-blind placebo-controlled trial. Chest. 2023;164(3):625–36.
doi: 10.1016/j.chest.2023.03.040 pubmed: 37011709 pmcid: 10808072

Auteurs

Logan S Gardner (LS)

School of Public Health and Preventive Medicine, Monash University, Clayton, Australia. logan.gardner@monash.edu.
ICPMR, NSW Health Pathology, Westmead Hospital, Sydney, Australia. logan.gardner@monash.edu.
Department of Immunology, Westmead Hospital, Westmead, Sydney, Australia. logan.gardner@monash.edu.

Lachlin Vaughan (L)

ICPMR, NSW Health Pathology, Westmead Hospital, Sydney, Australia.
The Lowy Cancer Research Centre, Kensington, Australia.

Danielle T Avery (DT)

Garvan Institute of Medical Research, Darlinghurst, Australia.

Isabelle Meyts (I)

Department of Immunology and Microbiology, Laboratory for Inborn Errors of Immunity, Department of Pediatrics, University Hospitals Leuven and KU Leuven, Leuven, EU, Belgium.

Cindy S Ma (CS)

Garvan Institute of Medical Research, Darlinghurst, Australia.
Clinical Immunogenomics Research Consortium of Australasia (CIRCA), Darlinghurst, Australia.
Faculty of Medicine and Health, St Vincent's Clinical School, UNSW Sydney, Sydney, Australia.

Stuart G Tangye (SG)

Garvan Institute of Medical Research, Darlinghurst, Australia.
Clinical Immunogenomics Research Consortium of Australasia (CIRCA), Darlinghurst, Australia.
Faculty of Medicine and Health, St Vincent's Clinical School, UNSW Sydney, Sydney, Australia.

Winny Varikatt (W)

ICPMR, NSW Health Pathology, Westmead Hospital, Sydney, Australia.
Faculty of Medicine, University of Sydney, Camperdown, Australia.

Ming-Wei Lin (MW)

ICPMR, NSW Health Pathology, Westmead Hospital, Sydney, Australia.
Faculty of Medicine, University of Sydney, Camperdown, Australia.
Clinical Immunogenomics Research Consortium of Australasia (CIRCA), Darlinghurst, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Development of EBV Related Diffuse Large...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Lymphomes › Lymphome malin non hodgkinien › Lymphome B › Lymphome B diffus à grandes cellules › Development of EBV Related Diffuse Large...
questionsmedicales.fr › Infection › Maladies virales › Infections à virus oncogènes › Infections à virus Epstein-Barr › Development of EBV Related Diffuse Large...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Aminohydrolases › Nucleoside deaminases › Adenosine deaminase › Development of EBV Related Diffuse Large...
questionsmedicales.fr › Virus › Virus oncogènes › Virus tumoraux à ADN › Gammaherpesvirinae › Lymphocryptovirus › Herpèsvirus humain de type 4 › Development of EBV Related Diffuse Large...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Development of EBV Related Diffuse Large...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies génétiques de la peau › Maladies auto-inflammatoires héréditaires › Development of EBV Related Diffuse Large...